- Home
- JJSF vs RLAY Comparison
JJSF vs RLAY Comparison
Compare JJSF & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JJSF
- RLAY
- Stock Information
- Founded
- JJSF 1971
- RLAY 2015
- Country
- JJSF United States
- RLAY United States
- Employees
- JJSF N/A
- RLAY N/A
- Industry
- JJSF Specialty Foods
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JJSF Consumer Staples
- RLAY Health Care
- Exchange
- JJSF Nasdaq
- RLAY Nasdaq
- Market Cap
- JJSF N/A
- RLAY 576.1M
- IPO Year
- JJSF N/A
- RLAY 2020
- Fundamental
- Price
- JJSF $112.54
- RLAY $3.38
- Analyst Decision
- JJSF Buy
- RLAY Strong Buy
- Analyst Count
- JJSF 2
- RLAY 11
- Target Price
- JJSF $142.50
- RLAY $18.40
- AVG Volume (30 Days)
- JJSF 179.4K
- RLAY 1.6M
- Earning Date
- JJSF 08-04-2025
- RLAY 08-05-2025
- Dividend Yield
- JJSF 2.79%
- RLAY N/A
- EPS Growth
- JJSF N/A
- RLAY N/A
- EPS
- JJSF 3.89
- RLAY N/A
- Revenue
- JJSF $1,585,410,000.00
- RLAY $7,679,000.00
- Revenue This Year
- JJSF $3.64
- RLAY $14.31
- Revenue Next Year
- JJSF $3.68
- RLAY N/A
- P/E Ratio
- JJSF $28.71
- RLAY N/A
- Revenue Growth
- JJSF 0.49
- RLAY N/A
- 52 Week Low
- JJSF $109.71
- RLAY $1.78
- 52 Week High
- JJSF $180.80
- RLAY $10.72
- Technical
- Relative Strength Index (RSI)
- JJSF 49.88
- RLAY 54.31
- Support Level
- JJSF $111.84
- RLAY $3.10
- Resistance Level
- JJSF $116.06
- RLAY $3.37
- Average True Range (ATR)
- JJSF 2.86
- RLAY 0.24
- MACD
- JJSF 0.42
- RLAY -0.01
- Stochastic Oscillator
- JJSF 50.25
- RLAY 51.52
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).